Published in Gastroenterology on August 11, 2010
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Hepatitis E virus infection. Clin Microbiol Rev (2014) 2.21
Molecular virology of hepatitis E virus. Virus Res (2011) 1.80
Genotype 3 diversity and quantification of hepatitis E virus RNA. J Clin Microbiol (2012) 1.11
World Health Organization International Standard to harmonize assays for detection of hepatitis E virus RNA. Emerg Infect Dis (2013) 1.04
A naturally occurring human/hepatitis E recombinant virus predominates in serum but not in faeces of a chronic hepatitis E patient and has a growth advantage in cell culture. J Gen Virol (2011) 1.01
Culture systems for hepatitis E virus. J Gastroenterol (2012) 0.98
Neurologic Disorders in Immunocompetent Patients with Autochthonous Acute Hepatitis E. Emerg Infect Dis (2015) 0.98
Mystery of hepatitis e virus: recent advances in its diagnosis and management. Int J Hepatol (2015) 0.95
Hepatitis E virus infection: Epidemiology and treatment implications. World J Virol (2015) 0.95
Chronic hepatitis e virus infection and treatment. J Clin Exp Hepatol (2013) 0.94
Hepatitis e virus infection in Iranian kidney-transplant patients. Hepat Mon (2011) 0.87
Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. Antimicrob Agents Chemother (2016) 0.84
Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infect Dis (2015) 0.82
Hepatitis E and Acute-on-Chronic Liver Failure. J Clin Exp Hepatol (2013) 0.82
Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis. J Clin Transl Hepatol (2016) 0.81
Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis. Viruses (2016) 0.81
Hepatitis E: an old infection with new implications. Blood Transfus (2014) 0.80
Hepatitis E virus as an emerging zoonotic pathogen. J Vet Sci (2016) 0.79
Quantification of HEV RNA by Droplet Digital PCR. Viruses (2016) 0.78
Hepatitis B and E co-primary infections in an HIV-1-infected patient. J Clin Microbiol (2013) 0.78
Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies. Emerg Infect Dis (2015) 0.77
Inhibition of hepatitis E virus replication by peptide-conjugated morpholino oligomers. Antiviral Res (2015) 0.77
Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particles. Proc Natl Acad Sci U S A (2017) 0.76
Chronic Hepatitis E Infection in a Persistently Immunosuppressed Patient Unable to Be Eliminated after Ribavirin Therapy. Intern Med (2016) 0.75
Hepatitis: Hepatitis E vaccination--is HEV 239 the breakthrough? Nat Rev Gastroenterol Hepatol (2011) 0.75
Hepatitis E Virus Infection after Platelet Transfusion in an Immunocompetent Trauma Patient. Emerg Infect Dis (2017) 0.75
Hepatitis E Virus in Industrialized Countries: The Silent Threat. Biomed Res Int (2016) 0.75
Molecular Biology and Infection of Hepatitis E Virus. Front Microbiol (2016) 0.75
Zinc salts block Hepatitis E virus replication by inhibiting the activity of viral RNA-dependent RNA polymerase. J Virol (2017) 0.75
Hepatitis E: A Literature Review. J Clin Transl Hepatol (2017) 0.75
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med (2008) 6.60
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med (2016) 5.31
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
Hepatitis E. Lancet (2012) 4.43
Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med (2012) 2.98
Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis (2011) 2.75
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol (2010) 2.51
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 2.47
"A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology (2002) 2.37
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood (2009) 2.33
Hepatitis E virus infection. Clin Microbiol Rev (2014) 2.21
Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS (2008) 2.04
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis (2009) 1.99
Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol (2004) 1.85
Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant (2005) 1.84
High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France. J Med Virol (2008) 1.84
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis (2010) 1.75
Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med (2012) 1.73
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73
Hepatitis E virus and neurologic disorders. Emerg Infect Dis (2011) 1.70
Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int (2007) 1.66
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr (2005) 1.63
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol (2013) 1.59
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int (2011) 1.53
An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation (2015) 1.52
Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol (2010) 1.49
Does chronic hepatitis E virus infection exist in immunocompetent patients? Hepatology (2014) 1.49
Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest (2011) 1.49
Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant (2010) 1.48
Anti-human leukocyte antigen immunization after early allograft nephrectomy. Transplantation (2012) 1.47
Hepatitis E is an autochthonous disease in industrialized countries. Analysis of 23 patients in South-West France over a 13-month period and comparison with hepatitis A. Gastroenterol Clin Biol (2006) 1.47
Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol (2012) 1.46
Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol (2005) 1.45
The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation (2004) 1.44
Ethanol lock and risk of hemodialysis catheter infection in critically ill patients. A randomized controlled trial. Am J Respir Crit Care Med (2015) 1.44
Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation (2010) 1.44
Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant (2007) 1.43
HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One (2009) 1.42
Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation (2007) 1.41
Occult hepatitis C virus infection in hemodialysis patients: examining the evidence. Am J Kidney Dis (2009) 1.39
Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol (2007) 1.39
R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2005) 1.37
Hepatitis E virus strains in rabbits and evidence of a closely related strain in humans, France. Emerg Infect Dis (2012) 1.37
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36